Sanofi's New Leadership Faces Looming Patent Cliff
Sanofi's wide lineup of branded drugs and vaccines and robust pipeline creates strong cash flows and a narrow economic moat.
Sanofi SA SAN
Bulls Say, Bears Say
Bulls
Immunology drug Dupixent holds strong pricing power and market share across several indications.
Bears
Sanofi suffered several disappointing readouts starting in 2025, adding pressure to develop or acquire assets that could replace Dupixent before its loss of exclusivity.
News
-
Sanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID®
-
Sanofi, Regeneron to Expand Alliance in Up to $8 Billion Deal — Update
-
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion
-
European Pharma Leaders Push for National Reforms to Boost Investment
-
Sanofi to Take Stake in Cheplapharm in Swap for Drug Portfolio, Manufacturing Sites
-
Sanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID™
-
Sanofi and Keke Palmer team up to urge parents to help protect babies from serious RSV with BEYFORTUS®
-
FDA Approves Seasonal Covid-19 Vaccines From Moderna, Pfizer, BioNTech, Novavax — Update
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 1.20B
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 12.11
- Price/Sales
- 1.81
- Dividend Yield (Trailing)
- 5.64%
- Dividend Yield (Forward)
- 5.64%
- Dividend Payment Schedule
- May
- Total Yield
- 11.18%
Company Profile
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 74,846
- Website
- https://www.sanofi.com
Competitors
Valuation
|
Metric
|
SAN
|
NVS
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 12.11 | 13.57 | 44.80 |
Price/Book Value | 1.38 | 6.45 | 8.47 |
Price/Sales | 1.81 | 4.80 | 5.36 |
Price/Cash Flow | 7.49 | 14.16 | 16.10 |
Price/Earnings
SAN
NVS
MRK
Financial Strength
|
Metric
|
SAN
|
NVS
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.49 | 0.55 | 0.71 |
Current Ratio | 0.99 | 0.86 | 1.32 |
Interest Coverage | 8.05 | 11.90 | 4.28 |
Quick Ratio
SAN
NVS
MRK
Profitability
|
Metric
|
SAN
|
NVS
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 7.96% | 14.74% | 6.27% |
Return on Equity (Normalized) | 14.96% | 39.06% | 16.68% |
Return on Invested Capital (Normalized) | 11.28% | 21.25% | 9.82% |
Return on Assets
SAN
NVS
MRK
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|C@rGm>kT | LOCK|Rc | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|L%DWp% | LOCK|WX | $623B | |||
| AbbVie Inc
ABBV
| LOCK|QKDGcG< | LOCK|@% | $459B | |||
| Merck & Co Inc
MRK
| LOCK|>&zJ!!@ | LOCK|<Qh | $355B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|rT^Gts&% | LOCK|!X | $334B | |||
| Novartis AG ADR
NVS
| LOCK|DScyThB | LOCK|?! | $268B | |||
| AstraZeneca PLC
AZN
| LOCK|^#<V?X!J | LOCK|X< | $248B | |||
| Amgen Inc
AMGN
| LOCK|<zD%xn> | LOCK|Sz | $220B | |||
| Gilead Sciences Inc
GILD
| LOCK|cpH&Cyr | LOCK|dq | $183B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|fZ#Vv$% | LOCK|<V | $167B |
United States